NCCN Guidelines for Patients® | Non-Small Cell Lung Cancer - page 75

75
NCCN Guidelines for Patients
®
: Non-Small Cell Lung Cancer
Version 1.2014
Part 7: Treatment by cancer stage
Par t 1
Par t 2
Par t 3
Par t 4
Par t 5
Par t 6
Par t 7
Par t 8
Par t 9
Notes:
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
_____________________
Maintenance therapy
Histology First-line treatment
Continuation maintenance
Squamous
Cetuximab + cisplatin and
vinorelbine
Cetuximab
Cisplatin and gemcitabine
Gemcitabine
Non-squamous Cetuximab + cisplatin and
vinorelbine
Cetuximab
Bevacizumab + carboplatin and
paclitaxel
Bevacizumab
Bevacizumab + pemetrexed and
a platinum chemotherapy drug
Bevacizumab + pemetrexed
Cisplatin and pemetrexed
Pemetrexed
Cisplatin and gemcitabine
Gemcitabine
Histology First-line treatment
Continuation maintenance
Squamous
Platinum-doublet chemotherapy Erlotinib or docetaxel
Non-squamous Platinum-doublet chemotherapy Erlotinib or pemetrexed
If there’s no cancer growth during the chemotherapy cycles, you may stay on some
of your first-line treatments. This is called continuation maintenance. Another option
is changing to a drug that you didn’t take as a first-line treatment. This is called
switch maintenance. Maintenance treatments supported by research are listed in
the chart above. A third option is to start close observation. Observation is a period
of testing to watch for cancer growth. If the cancer grows during maintenance or
observation, read
Treatments after first line
on page 76.
1...,65,66,67,68,69,70,71,72,73,74 76,77,78,79,80,81,82,83,84,85,...108
Powered by FlippingBook